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8.1
Proliferation as a prognostic tool in primary and metastatic
cancer
R. Parwaresch, Inst. ofHaemopathology, University ofKiel, Germany
Cellular proliferative activity is strictly regulated by a complicated
set ofpromotory and inhibitory array ofproteins. Despite the close
interaction and combinatorial function, the expression and deletion
of these factors is precisely time-dependent. Nevertheless, hardly
any of these factors fulfill the requirements as a proliferation
marker. Rare exceptions are the p350 (Ki-67) and the p170
(topoisomerase-II-alpha). In the last 10 years different attempts to
utilize these factors as proliferation and prognosis factor in cases
ofmalignant tumors have been only partially successful. Specially,
no significant difference could be detected between primary tumors
and cancers with overt metastases. This is at least partially due to
Gl-arrest ofthe tumor cells. The recently introduced proliferation
specific p100 seems to overcome this shortcoming. p100 reveals to
represent the most powerful tool oftumorprognosis, surpassing all
hitherto applied parameters. Primary foci of various cancer types
and late propagation stages reveal significantly different cell cycle
rates.
Novel generation of proliferation markers render insight into
renewal capacity of cancer cell populations. They can thus be
reliably used for the clincialprediction ofcancer outcome.
8.3
Cyfra 21-1 - A prognostic factor for patients with carcinoma
ofhead and neck unrelated to the stage ofthe disease
I. Doweck, M. Barak, N. Uri, E. Greenberg, Dept. of ORL,
Biochemistry Research Unit, Carmel Medical Center, Haifa, Israel
Cyfra 21-1 was reported as a possible tumor marker for squamous
cell carcinoma ofhead and neck (H&N) but its prognostic value is
not known. In the present study we evaluated the prognostic value
ofCyfra21-1 forthe survival ofpatients with carcinoma ofH&N.
The study included 67 patients with primary detection of
carcinoma of H&N. The parameters which were included in the
study were: Cyfra21-1 levels and the stage at the initial diagnosis,
period offollow up, and patients status, alive or dead.
Thirty two patients had low levels ofCyfra 21-1 at the diagnosis
(<1.5 ng/ml). Twenty three ofthem (72%) are alive and 9 (28%)
died. Thirty five patients had Cyfra 21-1 levels above 1.5 ng/ml 15
of them are alive (43%) and 20 died (57%). Using the Kaplan-
Meiers survival table, the survival rate ofall patients is 37% for 44
months. Patients with Cyfra21-1 below 1.5 ng/ml had a survival
rate of63% for 40 months in comparison to 20% in patients with
Cyfra 21-1 levels above 1.5 ng/ml. The odd's ratio of Ln (Cyfra
21-1) is 1.62 (p<0.03). In a Cox's regression model which
included the stage ofthe disease and Ln (Cyfra 21-1) it was found
that both the stage and Ln (Cyfra 21-1) are related to survival.
However, the model prefers the Ln (Cyfra 21-1) as the mai
parameter for prediction ofthe survival ofthese patients.
Conclusions: Cyfra 21-1 is a prognostic factor for patients with
carcinoma ofH&N, unrelated to the stage ofthe disease.
8.2
Metastatic potential is independent of primary tumor growth
rate in head and neck cancer patients
S. Edstrom, E. Cvetkovska, C. Lundberg, C. Wedenberg, Dept. of
Otolaryngology, Head and Neck Surgery, University ofGoteborg, Sweden
The management of cervical lymph nodes is a vitally important
component ofthe overall treatment strategy for patients with cancers of
the head and neck. Involvement of regional lymphatics by the primary
tumor is influenced by site, size and histomorphological features. In this
study we have investigated whether growth rate ofthe primary tumor is
related to the risk ofregional spread in head and neck cancer.
Methods and patients: 121 untreated patients with oropharyngeal
cancer were intraveneously injected with a synthetic pyrimidine analogue
(Bromodeoxyuridine; BrdU), which is incorporated into cell nuclei
actively synthesizing DNA. Following denaturation of DNA, the epitope
on BrdU will be able for binding ofa complex ofprimary and secondary
antibodies which can be identified by means ofbivariate flow cytometry.
In this way BrdUcan be demonstrated through thetransit ofthe cell cycle
and the cell division rate of the tumor can be determined. 32 of these
cancer tissues were also examined for the presence of p53 staining by
means ofimmunohistochemistry (Pb1801+DO7).
Results: The mean age ofthe cancer patients was 66 ± 2 years (SEM).
76 of the tumors were classified as NO while the others (n=45) were
classified as NI-N3. The primary tumors without regional metastases
demonstrated monoclonicity in 67%, BrdU uptake: 10.2 ± 0.9%, and
potential doublingtime: 113.2 ± 17.6 hours. These observations were not
different compared to thosetumors with palpablenodes. Furthermore, the
number ofprimary tumors with overexpression ofp53 (2 20%) was not
increased in those with regional metastases.
Conclusions: The growth rate ofhead and neck cancer has no influence
on the occurrffence ofregional metastasis.
8.4
Influence of positive neck on odds ratio for mortality in
patients with head and neck carcinomas in Oslo
H. Faye-Lund, Ullevaal University Hospital, Oslo, Norway
A material of 433 patients with head and neck carcinomas is
presented. Ofthe patients 1/3 presented with regional metastases.
The treatment-protocol of regional metastases goes as follows:
Preoperative irradiation (5OGy) followed by radical neck
dissection, if the primary tumour seems under control by
irradiation or surgery. The 5-year survival for the total cohort was
53%, 51% for men and 58% for women. Survival for respective
stages I-IV were as follows: 74%, 73%, 65% and 22%. Odds ratio
(OR) for mortality relative to regional metastases were: OR=2 for
N1, OR=3.5 for N2 and OR=8 for N3 compared to NO=1.Prognostic factors 33
8.5
Survival rates ofpatients with head and neck cancer
T.P.U. Wustrow, N. Maier, Arco-Palais, Munich, Germany
From 1979 to 1985 1217 patients with primary head and neck
cancer in the major areas have been treated at the LMU Miinchen,
Klinikum GroBhadem in Munich and thereafter followed for 10
years. The patients were grouped according to their tumor sites
(492 larynx, 184 hypopharynx, 238 oropharynx, 303 oral cavity)
and TNM-stages. For the patients with N+ stages the neck was
divided according to the lymph node regions (levels) proposed by
Robbins. From the 492 laryngeal patients 28% presented with
positive lymph nodes in glottic cancer and the longest survival
rates after 5 year were observed in those with positive nodes in
regions II (83,1%) and III (76,5%), whereas regions IV (162,5%)
and V (66,7%) showed significantly reduced survival rates.
Supraglottic cancers with positive nodes in regions 11(20,1%) and
V (20,0%) or the contralateral neck achieved significautly shorter
survival rates than those ofthe other neck regions. Similar results
were gained from other primary like in the mouth, oropharynx and
hypopharynx. The different lymphatic drainages have, however, to
be considered as will be presented at the conference.
9.3
Proposal of a prognostic relevant pN classification of cervical
lymph nodes
H. Glanz, Dept. of Otorhinolaryngology, University of Giel3en,
Germany
Background and Objective: Metastases of the cervical lymph nodes have decisive
influence on the prognosis in patients with head and neck cancer, especially with
laryngeal cancer, where local recurrences are rarely observed. The N-classification
system of the UICC is complicated, not easily applicable and shows many
disadvantages and mistakes. Especially difficult are: the pN categories are identical
with N categories, the dimensions of lymph node involvement are not relevant and
inportant parameters are not taken into consideration.
Material and method: 4665 cervical lymph nodes harvested after primary neck
dissection in 151 patients with laryngeal cancer were examined histologically.
Metastases were found in all 330 lymph nodes and were classified according to size,
number, site in the neck and extranodal tumor spread. These parameters were
correlated with survival rates.
Results: 21% of the metastases were only distinguished by pathohistological
examination in pNO / pN+. Only 7% of all metastases were larger than 3 cm in
diameter. Metastases largerthan 1 cm in diameter have a bad prognosis, which is even
worse over 2 cm in diameter. A significant correlation between follow-up and number
of lymph nodes involved was observed. Survival rates were good in cases with
metastases in one lymph node (90%), got worse in cases with 2 metastases (50%). In
cases with more than 2 lymph nodes involved, the survival rate dropped to 20%. The
metastases in the lower level oftheneck correlated with a low survival rate in contrast
to metastases in the upper two levels. The last parameter, extranodal growth or
extracapsular spread, which have not been considered in the TNM-classification so far,
showed significant evidence of prognostic relevance. These results of a former
investigation are confirmed by similar and more recent ones. They also apply to other
head and neck cancer. The level ofinvolvement is adjusted to the system ofRobin.
Conclusion: Based on our results, we propose the following new classification system
forpN:
pNO: Histologically no evidence ofmetastases
pNl: Unilateral metastases upto 2 cm in diameter in the uppertwo thirds ofthe
neck (Robin I - III), no extracapsular spread.
pN2: Morethan 2 unilateral or bilateral metastases in the upper two thirds ofthe
neck (Robin I - 11) largerthan 2 cm in diameter, no extracapsular spread.
pN3: Identical withpN2, but with extracapsular spread and / or metastases in the
lowerthird oftheneck (Robin IV - VI).
An N-classification will be proposed. accordingto pN.
9.4
Surgical treatment of the NO neck - indications and choice of
operation
W.I. Wei, Division of Otorhinolaryngology, Head & Neck Surgery, Dept. of
Surgery, University ofHongKong, China
The risk of subclinical nodal metastasis in head and neck cancer
increases with increasing T stage. Forty percent of patients with
early carcinoma of the tongue have subclinical cervical lymph
nodes (CLN) metastases on presentation and the corresponding
values for primary carcinoma ofthe oral cavity, hypopharynx and
tongue base are 35%, 40% and 55%. These lymph nodes should be
treated electively to improve survival and regional tumour control.
In view of associated morbidity radical neck dissection (RND)
should not be performed for NO neck because of the associated
morbidity. Modified neck dissection (MND) removes all the CLN
with micrometastasis and creates space for transposition offlaps.
Selective neck dissection (SND) removes clinically non-palpable,
yet diseased nodes, for pathological examiniation; postoperative
radiotherapy should be given for patients with extracapsular nodal
extension.
In a study ofRNDperformed in 384 patients at the Head andNeck
Division of the Department of Surgery, The University of Hong
Kong at Queen Mary Hospital, an association was found between
the location ofthe primarytumour and the level ofnodal metatasis.
In patients with primary carcinoma ofthe larynx or hypopharynx,
most involved CLN were in levels II, I and IV. For carcinoma of
the tongue and oral cavity, the affected CLN were in levels I, H
and mI and for oropharyngeal carcinoma, in levels II and m.
In summary the surgical treatment ofthe NO neck should be MIND
if space is required to accommodate a flap and SND should
remove nodes in those regionsthat drain the primarytumour.